ESC: Extending Angiomax after PCI Unhelpful (CME/CE)
(MedPage Today) -- Bleeding and stent thrombosis not influenced by continuation of treatment (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 1, 2015 Category: Cardiology Source Type: news

Court Rules Patents for Medicines Co.'s Anticlotting Drug Invalid
Medicines Co. said Thursday that a federal circuit court has ruled against the company in its patent suit against Hospira Inc., deeming the patents for its anticlotting drug Angiomax invalid. (Source: WSJ.com: Health)
Source: WSJ.com: Health - July 2, 2015 Category: Pharmaceuticals Tags: PAID Source Type: news

Disparate Narratives on Bivalirudin PersistDisparate Narratives on Bivalirudin Persist
Whether bivalirudin is associated with lower bleeding and mortality in primary PCI vs heparin and a similar level of glycoprotein IIb/IIIa remains the topic of debate after MATRIX and BRIGHT. theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 11, 2015 Category: Cardiology Tags: Cardiology Article Source Type: news

Bivalirudin in Primary PCI: Squaring the DataBivalirudin in Primary PCI: Squaring the Data
With multiple trials using different drug regimens and dosing, Drs Steg and Storey try to make sense of the findings on bivalirudin in primary PCI. theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 10, 2015 Category: Cardiology Tags: Cardiology Commentary Source Type: news

BRIGHT: Bivalirudin Bests Heparin, but Dose May MatterBRIGHT: Bivalirudin Bests Heparin, but Dose May Matter
Debate over bivalirudin vs heparin continues with the print publication of BRIGHT. But experts shed some light on why results were better for bivalirudin here than in the recent HEAT-PPC trial. Heartwire from Medscape (Source: theHeart.org)
Source: theHeart.org - April 13, 2015 Category: Cardiology Tags: Cardiology News Source Type: news

Sun Pharma settles Angiomax litigation with The Medicines Company
Under the terms of the agreement, the company's subsidiary is entitled to launch its version of generic Angiomax in the US on June 30, 2019. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 1, 2015 Category: Pharmaceuticals Source Type: news

MATRIX: Bivalirudin Reduced Mortality vs UFH in ACS SettingMATRIX: Bivalirudin Reduced Mortality vs UFH in ACS Setting
On its primary MACE end point, the MATRIX study missed in showing the superiority of bivalirudin over unfractionated heparin in ACS patients undergoing PCI, but mortality and bleeding advantages were observed. Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 20, 2015 Category: Cardiology Tags: Cardiology News Source Type: news

ACC: MATRIX Scores for Transradial
(MedPage Today) -- But Angiomax again comes up short against unfractioned heparin. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 18, 2015 Category: Cardiology Source Type: news

Findings from the BRIGHT trial published in JAMA
(Cardiovascular Research Foundation) Data from the BRIGHT trial published today in the Journal of the American Medical Association demonstrated that bivalirudin was superior to both heparin monotherapy and heparin plus tirofiban for patients with acute myocardial infarction undergoing percutaneous coronary intervention. Findings were first reported at last year's Transcatheter Cardiovascular Therapeutics, the annual scientific symposium of the Cardiovascular Research Foundation. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 17, 2015 Category: Global & Universal Source Type: news

Trial of bivalirudin during angioplasty reports mixed results
(American College of Cardiology) Patients with acute coronary syndrome undergoing angioplasty who received the anticoagulant drug bivalirudin did not show significant improvements in either of two co-primary endpoints -- a composite of rate of death, heart attack or stroke at 30 days, or a composite of those events plus major bleeding -- as compared to patients receiving standard anticoagulation therapy, according to a study presented at the American College of Cardiology's 64th Annual Scientific Session. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 16, 2015 Category: Global & Universal Source Type: news

The Medicines Company and SciClone Pharmaceuticals Establish Strategic Partnership for Two Cardiovascular Products in China
SciClone to Promote Potential Hospital Market Leaders in China, ANGIOMAX® (bivalirudin) and CLEVIPREX® (clevidipine) PARSIPPANY, N.J. & FOSTER CITY, Calif.--(Healthcare Sales & Marketing Network)--The Medicines Company (MDCO), a global biopharma... Biopharmaceuticals, LicensingThe Medicines Company, SciClone Pharmaceuticals, ANGIOMAX, CLEVIPREX (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 18, 2014 Category: Pharmaceuticals Source Type: news

Medicines Co wins patent infringement suit against Mylan
(Reuters) - A U.S. court ruled Mylan Inc infringed the Medicines Co's patent on its blood-clot-inhibitor Angiomax, according to a court filing on Monday. (Source: Reuters: Health)
Source: Reuters: Health - October 28, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

Bivalirudin vs Heparins With Bailout GP Iib/Iiia InhibitorsBivalirudin vs Heparins With Bailout GP Iib/Iiia Inhibitors
Find out more about the advantage of bivalirudin observed in comparison with heparins only with GPI used as bailout -- in patients with STEMI undergoing PCI. European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 20, 2014 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

TCT Hallway Buzz: The BRIGHT Trial
WASHINGTON (MedPage Today) -- The BRIGHT trial favored bivalirudin (Angiomax) over heparin in PCI, but was the heparin dose responsible? In this exclusive video, Rod H. Stables, MA, DM, discusses some caveats. (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - September 16, 2014 Category: Journals (General) Source Type: news

Light From BRIGHT: More Fuel for Bivalirudin-Heparin DebateLight From BRIGHT: More Fuel for Bivalirudin-Heparin Debate
US cardiologists are finally getting a look at the Chinese BRIGHT trial, heralded as the first three-way randomization of bivalirudin, heparin, and heparin plus a GP IIb/IIIa inhibitor. Heartwire (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 15, 2014 Category: Cardiology Tags: Cardiology News Source Type: news